litlas
Log inCreate account

Jonathan D. Cheng

Active 2000–2022

47
Papers
24,798
Citations
45
h-index
47
i10-index

Citations

Citations per year for Jonathan D. Cheng1945: 1 citations1995: 2 citations2002: 1 citations2003: 10 citations2004: 6 citations2005: 14 citations2006: 22 citations2007: 15 citations2008: 28 citations2009: 37 citations2010: 29 citations2011: 37 citations2012: 66 citations2013: 53 citations2014: 63 citations2015: 93 citations2016: 150 citations2017: 272 citations2018: 363 citations2019: 1,274 citations2020: 1,713 citations2021: 1,845 citations2022: 1,485 citations2023: 1,044 citations2024: 1,510 citations2025: 682 citations2026: 18 citations1946–1994: no citations, so these years are not shown1996–2001: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,308 citing papers, 24.5% of this breakdownChina: 2,473 citing papers, 18.3% of this breakdownGermany: 702 citing papers, 5.2% of this breakdownUnited Kingdom: 624 citing papers, 4.6% of this breakdownItaly: 603 citing papers, 4.5% of this breakdownJapan: 528 citing papers, 3.9% of this breakdownFrance: 485 citing papers, 3.6% of this breakdownCanada: 426 citing papers, 3.1% of this breakdownSpain: 414 citing papers, 3.1% of this breakdownSouth Korea: 345 citing papers, 2.6% of this breakdownNetherlands: 341 citing papers, 2.5% of this breakdownAustralia: 337 citing papers, 2.5% of this breakdown
0%24.5%Other 21.6%

Institutions

Fields

  • Medicine75.6%
  • Biochemistry, Genetics and Molecular Biology14.4%
  • Immunology and Microbiology7%
  • Engineering1.1%
  • Neuroscience0.5%
  • Mathematics0.2%
  • Other1.2%

Topics

  • Cancer Immunotherapy and Biomarkers18.1%
  • Immunotherapy and Immune Responses5.4%
  • Head and Neck Cancer Studies4%
  • Ferroptosis and cancer prognosis3.5%
  • CAR-T cell therapy research3.5%
  • Immune Cell Function and Interaction3.1%
  • Other62.4%

Coauthors

All papers

Open in search
  1. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

    Authors: Barbara Burtness, Kevin J. Harrington, Richard Greil, Denis Soulières, Makoto Tahara, Gilberto de Castro, Amanda Psyrri, Neus Basté, Prakash Neupane, Åse Bratland, Thorsten Fuereder, Brett Hughes, Ricard Mesı́a, Nuttapong Ngamphaiboon, Tamara Rordorf, Wan Zamaniah Wan Ishak, Ruey‐Long Hong, René González Mendoza, Ananya Roy, Yayan Zhang, Burak Gümüşçü, Jonathan D. Cheng, Fan Jin, Danny Rischin, Guillermo Lerzo, Marcelo Tatangelo, Mirta Varela, Juan José Zarbá, Michael Boyer, Hui Gan, Bo Gao, Brett Hughes, Girish Mallesara, Danny Rischin, Anne L. Taylor, Martin Burian, Thorsten Fuereder, Richard Greil, Carlos H. Barrios, Dalvaro Oliveira de Castro Junior, Gilberto de Castro, Fábio Franke, Gustavo Girotto, Iane Pinto Figueiredo Lima, Ulisses Ribaldo Nicolau, Gustavo Dix Junqueira Pinto, Lucas Vieira dos Santos, Ana-Paula Victorino, Neil Chua, Félix Couture, Richard Gregg, Aaron R. Hansen, John Hilton, Joy McCarthy, Denis Soulières, Rodrigo Ascuí, Pablo Gonzalez, Luis J. Villanueva-Rivera, Marco Torregroza, Ángela R. Zambrano, Petra Holečková, Zdeněk Král, Bohuslav Melichar, Prausova Jana, Milan Vošmik, Maria Andersen, Niels Gyldenkerne, Hannes Jürgens, Kadri Putnik, Petri Reinikainen, Viktor Gruenwald, Simon Laban, Gerasimos Aravantinos, Ioannis Boukovinas, Vassilis Georgoulias, Amanda Psyrri, D.L.W. Kwong, Yousuf Al-Farhat, Tibor Csőszi, József Erfán, Geza Horvai, László Landherr, Éva Remenár, Ágnes Ruzsa, Judit Szota, Salem Billan, Iris Gluck, Orit Gutfeld, Aron Popovtzer, Marco Benasso, Simona Bui, Vittorio Ferrari, Lisa Licitra, Franco Nolè, Takashi Fujii, Yasushi Fujimoto, Nobuhiro Hanai, Hiroki Hara, Koji Matsumoto, Kenji Mitsugi and 119 more - The Lancet 2019 cited by 3,211

  2. IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade

    Authors: Mark Ayers, Jared Lunceford, Michael Nebozhyn, Erin Murphy, Andrey Loboda, David R. Kaufman, Andrew Albright, Jonathan D. Cheng, Shijun Kang, Veena Shankaran, Sarina A. Piha‐Paul, Jennifer H. Yearley, Tanguy Y. Seiwert, Antoni Ribas, Terrill K. McClanahan - Journal of Clinical Investigation 2017 cited by 3,872

  3. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy

    Authors: Răzvan Cristescu, Robin Mogg, Mark Ayers, Andrew Albright, Erin Murphy, Jennifer H. Yearley, Xinwei Sher, Xiao Qiao Liu, Hongchao Lu, Michael Nebozhyn, Chunsheng Zhang, Jared Lunceford, Andrew K. Joe, Jonathan D. Cheng, Andrea L. Webber, Nageatte Ibrahim, Elizabeth R. Plimack, Patrick A. Ott, Tanguy Y. Seiwert, Antoni Ribas, Terrill K. McClanahan, Joanne E. Tomassini, Andrey Loboda, David R. Kaufman - Science 2018 cited by 2,380

  4. Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer

    Authors: Seung Tae Kim, Răzvan Cristescu, Adam J. Bass, Kyoung‐Mee Kim, Justin I. Odegaard, Kyung Kim, Xiao Qiao Liu, Xinwei Sher, Hun Jung, Mi-Jin Lee, Sujin Lee, Se Hoon Park, Joon Oh Park, Young Suk Park, Ho Yeong Lim, Hyuk Lee, Min Gew Choi, AmirAli Talasaz, Peter Kang, Jonathan D. Cheng, Andrey Loboda, Jeeyun Lee, Won Ki Kang - Nature Medicine 2018 cited by 1,717

  5. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study

    Authors: Ezra E.W. Cohen, Denis Soulières, Christophe Le Tourneau, José Dinis, Lisa Licitra, Myung‐Ju Ahn, Ainara Soria, Jean‐Pascal Machiels, Nicolas Mach, Ranee Mehra, Barbara Burtness, Pingye Zhang, Jonathan D. Cheng, Ramona F. Swaby, Kevin J. Harrington, Mirelis Acosta-Rivera, Douglas R. Adkins, Morteza Aghmesheh, Myung‐Ju Ahn, Mario Airoldi, Eduardas Aleknavičius, Yousuf Al-Farhat, Alain P. Algazi, Salah Almokadem, Anna Alyasova, Jessica R. Bauman, Marco Benasso, Alfonso Berrocal, Victoria Bray, Barbara Burtness, Francesco Caponigro, Ana Castro, Terrence P. Cescon, Kelvin Chan, Arvind Chaudhry, Bruno Chauffert, Ezra E.W. Cohen, Tibor Csőszi, Jan Paul de Boer, Jean‐Pierre Delord, Andreas Dietz, José Dinis, Charlotte Dupuis, Laurence Digue, József Erfán, Yolanda Escobar Alvarez, Mererid Evans, Mary J. Fidler, Martin Förster, Signe Friesland, Apar Kishor Ganti, Lionnel Geoffrois, Clíona Grant, Viktor Gruenwald, Kevin J. Harrington, Thomas K. Hoffmann, Geza Horvai, Arturas Inčiūra, Raymond Woo-Jun Jang, Petra Jankowska, Antonio Jimeno, Mano Joseph, Alejandro Juárez Ramiro, Bogusława Karaszewska, Andrzej Kawecki, Ulrich Keilholz, Ulrich Keller, Sung‐Bae Kim, Judit Kocsis, Nuria Kotecki, Mark Kozloff, J. Lambea, László Landherr, Yuri Lantsukhay, Sergey Lazarev, Lip Way Lee, Christophe Le Tourneau, Lisa Licitra, Igor Lifirenko, Nicolas Mach, Danko Martincic, О. В. Маторин, Margaret McGrath, Jean‐Pascal Machiels, Ranee Mehra, Krzysztof Misiukiewicz, John C. Morris, Ф. Ф. Муфазалов, Jiaxin Niu, Devraj Srinivasan, Pedro Pérez Segura, Daniel Rauch, Maria Leonor Ribeiro, Cristina P. Rodriguez, Frédéric Rolland, Antonio Russo, Ágnes Ruzsa, Frederico Sanches, Sangwon Shin, Mikhail Shtiveland and 13 more - The Lancet 2018 cited by 1,697

  6. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial

    Authors: Tanguy Y. Seiwert, Barbara Burtness, Ranee Mehra, Jared Weiss, Raanan Berger, Joseph P. Eder, Karl Heath, Terrill K. McClanahan, Jared Lunceford, Christine K. Gause, Jonathan D. Cheng, Laura Q.M. Chow - The Lancet Oncology 2016 cited by 1,740

  7. Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study

    Authors: Rita Nanda, Laura Q.M. Chow, Elizabeth Claire Dees, Raanan Berger, Shilpa Gupta, Ravit Geva, Lajos Pusztai, Kumudu Pathiraja, Gursel Aktan, Jonathan D. Cheng, Vassiliki Karantza, Laurence Buisseret - Journal of Clinical Oncology 2016 cited by 1,473

  8. PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer

    Authors: Jennifer H. Yearley, Christopher J. Gibson, Ni Yu, Christina Moon, Erin Murphy, Jonathan Juco, Jared Lunceford, Jonathan D. Cheng, Laura Q.M. Chow, Tanguy Y. Seiwert, Masahisa Handa, Joanne E. Tomassini, Terrill K. McClanahan - Clinical Cancer Research 2017 cited by 604

  9. Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012

    Authors: Ranee Mehra, Tanguy Y. Seiwert, Shilpa Gupta, Jared Weiss, Iris Gluck, Joseph P. Eder, Barbara Burtness, Makoto Tahara, Bhumsuk Keam, Hyunseok Kang, Kei Muro, Ravit Geva, Hyun Cheol Chung, Chia‐Chi Lin, Deepti Aurora-Garg, Archana Ray, Kumudu Pathiraja, Jonathan D. Cheng, Laura Q.M. Chow, Robert I. Haddad - British Journal of Cancer 2018 cited by 456

  10. Extended Structure–Activity Relationship and Pharmacokinetic Investigation of (4-Quinolinoyl)glycyl-2-cyanopyrrolidine Inhibitors of Fibroblast Activation Protein (FAP)

    Authors: Koen Jansen, Leen Heirbaut, Robert Verkerk, Jonathan D. Cheng, Jurgen Joossens, Paul Cos, Louis Maes, Anne‐Marie Lambeir, Ingrid De Meester, Koen Augustyns, Pieter Van der Veken - Journal of Medicinal Chemistry 2014 cited by 280

  11. Selective Inhibitors of Fibroblast Activation Protein (FAP) with a (4-Quinolinoyl)-glycyl-2-cyanopyrrolidine Scaffold

    Authors: Koen Jansen, Leen Heirbaut, Jonathan D. Cheng, Jurgen Joossens, O.V. Ryabtsova, Paul Cos, Louis Maes, Anne‐Marie Lambeir, Ingrid De Meester, Koen Augustyns, Pieter Van der Veken - ACS Medicinal Chemistry Letters 2013 cited by 260

  12. Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1–Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study

    Authors: Chiun Hsu, Se‐Hoon Lee, Samuel Ejadi, Caroline Even, Roger B. Cohen, Christophe Le Tourneau, Janice M. Mehnert, Alain P. Algazi, Emilie M.J. van Brummelen, Sanatan Saraf, Pradeep Thanigaimani, Jonathan D. Cheng, Aaron R. Hansen - Journal of Clinical Oncology 2017 cited by 471

  13. Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study

    Authors: Joshua Bauml, Tanguy Y. Seiwert, David G. Pfister, Francis P. Worden, Stephen V. Liu, Jill Gilbert, Nabil F. Saba, Jared Weiss, Lori J. Wirth, Ammar Sukari, Hyunseok Kang, Michael K. Gibson, Erminia Massarelli, Steven Powell, Amy Meister, Xinxin Shu, Jonathan D. Cheng, Robert I. Haddad - Journal of Clinical Oncology 2017 cited by 652

  14. Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort

    Authors: Laura Q.M. Chow, Robert I. Haddad, Shilpa Gupta, Amit Mahipal, Ranee Mehra, Makoto Tahara, Raanan Berger, Joseph P. Eder, Barbara Burtness, Se‐Hoon Lee, Bhumsuk Keam, Hyunseok Kang, Kei Muro, Jared Weiss, Ravit Geva, Chia‐Chi Lin, Hyun Cheol Chung, Amy Meister, Marisa Dolled‐Filhart, Kumudu Pathiraja, Jonathan D. Cheng, Tanguy Y. Seiwert - Journal of Clinical Oncology 2016 cited by 859

  15. Phase II trial of single agent Val-boroPro (talabostat) inhibiting fibroblast activation protein in patients with metastatic colorectal cancer

    Authors: Kalyani Narra, Stefanie Mullins, Hyung-Ok Lee, Brenda Strzemkowski-Brun, K. Magalong, Victoria J. Christiansen, Patrick A. McKee, Brian L. Egleston, Steven J. Cohen, Louis M. Weiner, Neal J. Meropol, Jonathan D. Cheng - Cancer Biology & Therapy 2007 cited by 270

  16. Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced, PD-L1–positive papillary or follicular thyroid cancer

    Authors: Janice M. Mehnert, Andréa Varga, Marcia S. Brose, Rahul Aggarwal, Chia‐Chi Lin, Amy Prawira, Filippo de Braud, Kenji Tamura, Toshihiko Doi, Sarina A. Piha‐Paul, Jill Gilbert, Sanatan Saraf, Pradeep Thanigaimani, Jonathan D. Cheng, Bhumsuk Keam - BMC Cancer 2019 cited by 221

  17. Talimogene Laherparepvec and Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY-232): A Multicenter, Phase 1b Study

    Authors: Kevin J. Harrington, Anthony Kong, Nicolas Mach, Jason Chesney, Beatriz Castelo Fernández, Danny Rischin, Ezra E.W. Cohen, Hoi-Shen Radcliffe, Burak Gümüşçü, Jonathan D. Cheng, Wendy Snyder, Lillian L. Siu - Clinical Cancer Research 2020 cited by 108

  18. Clinical Implications of Fibroblast Activation Protein in Patients with Colon Cancer

    Authors: Leonard R. Henry, Hyung‐Ok Lee, John S. Lee, Andres J. Klein–Szanto, Perry Watts, Eric A. Ross, Wen‐Tien Chen, Jonathan D. Cheng - Clinical Cancer Research 2007 cited by 361

  19. Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer

    Authors: Janice M. Mehnert, Anshuman Panda, Judy Zhong, Kim M. Hirshfield, Sherri Damare, Katherine Lane, Levi Sokol, Mark N. Stein, Lorna Rodriguez-Rodriquez, Howard L. Kaufman, Siraj M. Ali, Jeffrey S. Ross, Dean C. Pavlick, Gyan Bhanot, Eileen White, Robert S. DiPaola, Ann Lovell, Jonathan D. Cheng, Shridar Ganesan - Journal of Clinical Investigation 2016 cited by 385

  20. FAP-overexpressing fibroblasts produce an extracellular matrix that enhances invasive velocity and directionality of pancreatic cancer cells

    Authors: Hyung‐Ok Lee, Stefanie Mullins, Janusz Franco‐Barraza, Matthildi Valianou, Edna Cukierman, Jonathan D. Cheng - BMC Cancer 2011 cited by 295

  21. Fibroblast Activation Protein and Its Relationship to Clinical Outcome in Pancreatic Adenocarcinoma

    Authors: Steven J. Cohen, R. Katherine Alpaugh, Irma Palazzo, Neal J. Meropol, André Rogatko, Zhiheng Xu, John P. Hoffman, Louis M. Weiner, Jonathan D. Cheng - Pancreas 2008 cited by 240

  22. Pembrolizumab for the Treatment of Advanced Salivary Gland Carcinoma

    Authors: Roger B. Cohen, Jean‐Pierre Delord, Toshihiko Doi, Sarina A. Piha‐Paul, Stephen V. Liu, Jill Gilbert, Alain P. Algazi, Silvia Damian, Ruey‐Long Hong, Christophe Le Tourneau, Daphne Day, Andréa Varga, Elena Élez, John M. Wallmark, Sanatan Saraf, Pradeep Thanigaimani, Jonathan D. Cheng, Bhumsuk Keam - American Journal of Clinical Oncology 2018 cited by 206

  23. Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma

    Authors: Robert I. Haddad, Tanguy Y. Seiwert, Laura Q.M. Chow, Shilpa Gupta, Jared Weiss, Iris Gluck, Joseph P. Eder, Barbara Burtness, Makoto Tahara, Bhumsuk Keam, Hyunseok Kang, Kei Muro, Andrew Albright, Robin Mogg, Mark Ayers, Lingkang Huang, Jared Lunceford, Răzvan Cristescu, Jonathan D. Cheng, Ranee Mehra - Journal for ImmunoTherapy of Cancer 2022 cited by 96

  24. Complete Response to Neoadjuvant Chemoradiotherapy in Esophageal Carcinoma Is Associated With Significantly Improved Survival

    Authors: Adam C. Berger, Jeffrey M. Farma, Walter J. Scott, Gary M. Freedman, Louis M. Weiner, Jonathan D. Cheng, Hao Wang, Melvyn Goldberg - Journal of Clinical Oncology 2005 cited by 518